Supplementary Table S3 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
The mutated residues in the yeast strains are presented in Table 2 for the Plasmodium-like mutants (PF) and in Table 3 for the human-like mutants (HS). Their location in the sequence and the structure
Differentially expressed genes and molecular pathways were identified after statin treatment in kidney cells and assessed in plasma samples of the AURORA cohort. Overall design: The impact of statin t
ERBB2 kinase domain mutations that were reported in solid cancers were shown along with their structural position and IC50 values against lapatinib and AEE 788. IC50 values were calculated based on Fi
